Dr. Mewawalla's work focuses on selecting and sequencing CAR T-cell therapy, bispecific antibodies, and transplantation, and building safe, practical pathways that bring advanced myeloma care closer to patients.
Newly diagnosed through multiply relapsed disease, with a practical focus on treatment selection at each decision point rather than one-size-fits-all algorithms.
Patient selection, timing, and sequencing after CAR T-cell therapy, plus operational work to shorten length of stay and safely broaden who can be treated.
Step-up dosing, toxicity management across BCMA- and GPRC5D-directed agents, and pathways that make community administration feasible.
AL amyloidosis, MGUS, and smoldering myeloma, including cardiac amyloid and the monitoring decisions that precede treatment.
Autologous transplantation and apheresis program leadership, from cell collection through comprehensive, accredited cellular therapy delivery.
Across all of these: which advanced therapy, when to use it, how to sequence what comes next, and how to make it accessible in the real world.
See the evidence